MSD Commited to bringing out the best in medicine
Contact UsWorldwide
   
Clinical Studies
Resources
Email Updates
Request More Information
Home Page Logo
FOSAMAX® ONCE WEEKLY OUTPERFORMED ACTONEL® ONCE A WEEK


 

FOSAMAX ONCE WEEKLY
ACTONEL ONCE-A-WEEK
COMPARISON
TRIAL

In the first and only head-to-head trial, FOSAMAX delivered1
  • Faster and superior reductions in bone turnover (p<0.001) - as early as 3 months1,*
  • Faster and superior increases in hip (p<0.001) and spine BMD (p=0.002) - as early as 6 months1
  • No significant difference in upper-GI or overall tolerability between treatment groups1
 

 
10 YEARS EXPERIENCE WITH FOSAMAX®
In Postmenopausal women:


The longest
Osteoporosis study ever1

FOSAMAX is the only osteoporosis therapy with proven efficacy through 10 years2
  • Sustained improvement in bone density2
  • Return bone turnover to normal pre-menopausal levels2
FOSAMAX has proven safety profile for long term use2
  • Non-vertebral fracture reduction sustained through 10 years2

  • Well tolerated - consistent with previous studies2

 
PREVENT HIP FRACTURES WITH FOSAMAX

FOSAMAX reduced the risk of hip fractures by 63% at 18 months (p=0.014 vs. placebo) 3

In the ORAG meta-analysis,4 FOSAMAX showed larger reductions in nonvertebral fracture risk when compared with other osteoporosis treatments.a
STOP VERTEBRAL FRACTURES WITH  FOSAMAX
  • No other agent in the class has reported faster results at the spine.5-9
  • Reduced risk of multiple symptomatic vertebral fractures in just
    6 months (p<0.044 vs. placebo).10
  • In the ORAG meta-analysis,4   FOSAMAX showed larger reductions in vertebral fracture risk when compared with other osteoporosis treatments.a

Before prescribing, please see full product circular.
For more information, see Study Designs.
a

Data not representative of head-to-head studies.
back to top
View ReferencesView References PrintPrint

† Registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA
LATEST DATA - FACT

 FOSAMAX® ONCE WEEKLY ACTONEL® ONCE-A-WEEK COMPARISON TRIAL.
Download Slide Set
LATEST DATA
The New England Journal of Medicine published the results of a landmark, 10-year study for FOSAMAX: "Ten Years' Experience with Alendronate for the Treatment of Osteoporosis in Postmenopausal Women"
 
Privacy Policy Terms of Use Copyright Merck & CO., Inc. (USA) Disclaimer